- Home
- CSCI vs CWD Comparison
CSCI vs CWD Comparison
Compare CSCI & CWD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CSCI
- CWD
- Stock Information
- Founded
- CSCI 1990
- CWD 2009
- Country
- CSCI Canada
- CWD United States
- Employees
- CSCI N/A
- CWD N/A
- Industry
- CSCI
- CWD Real Estate
- Sector
- CSCI
- CWD Finance
- Exchange
- CSCI NYSE
- CWD Nasdaq
- Market Cap
- CSCI 12.5M
- CWD 13.4M
- IPO Year
- CSCI 1996
- CWD 2023
- Fundamental
- Price
- CSCI $3.70
- CWD $0.60
- Analyst Decision
- CSCI
- CWD
- Analyst Count
- CSCI 0
- CWD 0
- Target Price
- CSCI N/A
- CWD N/A
- AVG Volume (30 Days)
- CSCI 5.3K
- CWD 57.8K
- Earning Date
- CSCI 11-07-2024
- CWD 11-07-2024
- Dividend Yield
- CSCI N/A
- CWD N/A
- EPS Growth
- CSCI N/A
- CWD N/A
- EPS
- CSCI N/A
- CWD N/A
- Revenue
- CSCI $4,915,000.00
- CWD $72,100,000.00
- Revenue This Year
- CSCI N/A
- CWD N/A
- Revenue Next Year
- CSCI N/A
- CWD $41.65
- P/E Ratio
- CSCI N/A
- CWD N/A
- Revenue Growth
- CSCI N/A
- CWD N/A
- 52 Week Low
- CSCI $3.49
- CWD $0.50
- 52 Week High
- CSCI $11.10
- CWD $1.74
- Technical
- Relative Strength Index (RSI)
- CSCI N/A
- CWD 47.14
- Support Level
- CSCI N/A
- CWD $0.51
- Resistance Level
- CSCI N/A
- CWD $0.76
- Average True Range (ATR)
- CSCI 0.00
- CWD 0.07
- MACD
- CSCI 0.00
- CWD -0.00
- Stochastic Oscillator
- CSCI 0.00
- CWD 35.96
About CSCI COSCIENS BIOPHARMA INC
Cosciens Biopharma Inc is a biopharmaceutical company developing and commercializing a diversified portfolio of pharmaceutical and diagnostic products and active ingredients for healthcare and cosmetics industries. The company is engaged in the development of therapeutic assets and proprietary extraction technology.
About CWD CaliberCos Inc.
CaliberCos Inc is an asset management firm, whose primary goal is to enhance the wealth of investors seeking to make investments in middle-market assets. The company's funds include investment vehicles focused on real estate, private equity, and debt facilities. The company earns asset management fees calculated as a percentage of managed capital in funds and offerings. The company markets services through direct sales to private investors, wholesaling to investment advisers, direct sales to family offices and institutions and through in-house client services. The company operates into three reportable segments: Fund Management, Development, and Brokerage. Majority of revenue is derived from Asset management fees segment.